FULL DETAILS (Read-only)  -> Click Here to Create PDF for Current Dataset of Trial
CTRI Number  CTRI/2022/04/041776 [Registered on: 11/04/2022] Trial Registered Prospectively
Last Modified On: 10/04/2022
Post Graduate Thesis  Yes 
Type of Trial  Interventional 
Type of Study   Drug
Surgical/Anesthesia 
Study Design  Randomized, Parallel Group Trial 
Public Title of Study   To decrease the side effects of spinal anaesthesia using different doses of drugs in Caesarean section 
Scientific Title of Study   Comparitive study of fixed dose versus height adjusted dose of heavy bupivacaine in spinal anaesthesia for elective caesarean section 
Trial Acronym   
Secondary IDs if Any  
Secondary ID  Identifier 
NIL  NIL 
 
Details of Principal Investigator or overall Trial Coordinator (multi-center study)  
Name  Dr Piu Gorai 
Designation  Junior Resident 
Affiliation  RIMS,Ranchi 
Address  Department of Anaesthesiology,RIMS,Ranchi, Jharkhand

Ranchi
JHARKHAND
834009
India 
Phone  8092760437  
Fax    
Email  mepiugorai@gmail.com  
 
Details of Contact Person
Scientific Query
 
Name  Dr Ekramul Haque 
Designation  Associate Professor 
Affiliation  RIMS,Ranchi 
Address  Department of Anaesthesiology, RIMS,Ranchi, Jharkhand

Ranchi
JHARKHAND
834009
India 
Phone  8210696628  
Fax    
Email  ekramrims@yahoo.co.in  
 
Details of Contact Person
Public Query
 
Name  Dr Ekramul Haque 
Designation  Associate Professor 
Affiliation  RIMS,Ranchi 
Address  Department of Anaesthesiology, RIMS,Ranchi,Jharkhand

Ranchi
JHARKHAND
834009
India 
Phone  8210696628  
Fax    
Email  ekramrims@yahoo.co.in  
 
Source of Monetary or Material Support  
RIMS,RANCHI 
 
Primary Sponsor  
Name  Rajendra Institute of Medical Sciences 
Address  Department of Anaesthesiology, RIMS,Ranchi 
Type of Sponsor  Government medical college 
 
Details of Secondary Sponsor  
Name  Address 
NIL  NIL 
 
Countries of Recruitment     India  
Sites of Study  
No of Sites = 1  
Name of Principal Investigator  Name of Site  Site Address  Phone/Fax/Email 
Dr Piu Gorai  RIMS,Ranchi  Department of Anaesthesiology, RIMS,Ranchi
Ranchi
JHARKHAND 
8092760437

mepiugorai@gmail.com 
 
Details of Ethics Committee  
No of Ethics Committees= 1  
Name of Committee  Approval Status 
Rajendra Institute of Medical Sciences,Ranchi  Approved 
 
Regulatory Clearance Status from DCGI  
Status 
Not Applicable 
 
Health Condition / Problems Studied  
Health Type  Condition 
Patients  (1) ICD-10 Condition: 1||Obstetrics, (2) ICD-10 Condition: O||Medical and Surgical, (3) ICD-10 Condition: 1||Obstetrics,  
 
Intervention / Comparator Agent  
Type  Name  Details 
Comparator Agent  Fixed dose group  Patient to recieve fixed dose 11mg(2.2ml) of 0.5% heavy bupivacaine intrathecally via spinal needle at the time of induction before caesarean section 
Intervention  Height based group  Patients to recieve height adjusted dose(0.06mg/cm) of 0.5% heavy bupivacaine intrathecally via spinal needle at the time of induction before caesarean section 
 
Inclusion Criteria  
Age From  21.00 Year(s)
Age To  40.00 Year(s)
Gender  Female 
Details  1.Patient consent
2.Age group - 21years to 40years scheduled for elective caesarean section
3.singleton pregnancy
4.Weight -40 to 80 kg
5.Height- 140cm-170cm
5.ASA II 
 
ExclusionCriteria 
Details  1.patient refusal
2.patient with contraindication to spinal anaesthesia
3.patient with cardiovascular disease,pre eclampsia,eclampsia and systolic BP<90 mmHg
4.Women with fetal abnormalities
5.women with placental abnormalities 
 
Method of Generating Random Sequence   Coin toss, Lottery, toss of dice, shuffling cards etc 
Method of Concealment   Sequentially numbered, sealed, opaque envelopes 
Blinding/Masking   Participant and Investigator Blinded 
Primary Outcome  
Outcome  TimePoints 
1.Incidence of maternal hypotension
2.Time to reach T8 sensory level
3.Maximum sensory level achieved and time to reach the same
4.Time taken for 2 segment sensory regression
5.Time to achieve modified bromage score 3


 
24 hrs 
 
Secondary Outcome  
Outcome  TimePoints 
1.Total dose of mephentermine consumption
2.APGAR score at 1 and 5 min
3.To study side effects such as nausea, vomiting ,headache 
24 hrs 
 
Target Sample Size   Total Sample Size="60"
Sample Size from India="60" 
Final Enrollment numbers achieved (Total)= "Applicable only for Completed/Terminated trials"
Final Enrollment numbers achieved (India)="Applicable only for Completed/Terminated trials" 
Phase of Trial   Phase 4 
Date of First Enrollment (India)   20/04/2022 
Date of Study Completion (India) Applicable only for Completed/Terminated trials 
Date of First Enrollment (Global)  Date Missing 
Date of Study Completion (Global) Applicable only for Completed/Terminated trials 
Estimated Duration of Trial   Years="1"
Months="6"
Days="0" 
Recruitment Status of Trial (Global)   Not Applicable 
Recruitment Status of Trial (India)  Not Yet Recruiting 
Publication Details   NIL 
Individual Participant Data (IPD) Sharing Statement

Will individual participant data (IPD) be shared publicly (including data dictionaries)?  

Response - NO
Brief Summary   This study is randomized double blind parallel group trial comparing height based optimization (0.06mg/cm) Vs fixed 11 mg/2.2 ml)of heavy bupivacaine in spinal anaesthesia for patients posted for elective caesarean section in RIMS Ranchi in INDIA.THE Primary objective is to study incidence of hypotension and block characteristics.The secondary objective is to study the total dose of mephentermine consumption and side effects.Inclusion criteria included singleton, uncomplicated pregnancy of ASA physical status II.The hypothesis of the study is height based optimization of dose of bupivacaine will minimize hypotension and would provide adequate anaesthesia for caesarean section.Various studies such as Huang B,Huang Q found that height adjusted dose of spinal anaesthesia in parturient provides sufficient anaesthesia and low incidence of maternal hypotension and that prophylactic fliluid preloading and vasopressor are unnecessary.
 Sabale P et al found that height based dose of  spinal anaesthesia decreases the chance of hypotension,need of vasopressor with better hemodynamic stability and decreased incidence of side effects
 
Close